One of the few Chinese pharmaceutical CROs with a complete technical platform covering parenteral nutrition lipid emulsions, drug-loaded lipid emulsion injections, multi-chamber bag injections, and Category 2.2 modified new drug lipid emulsions. With a portfolio of 20+ drug products, we provide end-to-end R&D services from formulation development to regulatory submission.
Lipid emulsion injections are among the highest-barrier categories in complex injectables. The key R&D challenges center on physical stability (Ostwald ripening), pre- and post-sterilization quality consistency, industrial-scale high-pressure homogenization scale-up, and control of free drug after drug loading. Taikomed is one of the few CROs in China with complete project experience across all four directions.
LCT / MCT-LCT / SMOF / Fish Oil / Olive Oil / Structured Lipid — Full-category coverage to meet diverse clinical parenteral nutrition needs.
Lipid emulsion as a carrier for poorly water-soluble drugs — generic development and process optimization for propofol, etomidate, flurbiprofen axetil, and other key products.
Lipid emulsion / amino acid / glucose 3-chamber bags, olive oil 3-chamber bags — multi-chamber packaging technology, container compatibility, and in-use stability studies.
Curcuma oil, silymarin, artesunate, and other TCM/natural drug lipid emulsion formulations — dosage form modification + clinical advantage demonstration + innovative regulatory pathways.
In the parenteral nutrition lipid emulsion space, Taikomed has established a complete R&D pipeline spanning from first-generation to latest-generation lipid emulsion injections. We are one of the only CROs in China with development experience across all categories: LCT, MCT/LCT, structured lipid, SMOF, fish oil, and olive oil lipid emulsions.
First-generation lipid emulsion with soybean oil as the oil phase. A classic product with a mature formulation, but oxidative stability remains a key focus.
Second-generation lipid emulsion. MCTs are metabolized faster with lower accumulation risk. Clinical utilization continues to rise. C6-C12 fatty acid composition is a key submission parameter.
Fourth-generation composite lipid emulsion — soybean oil + MCT + olive oil + fish oil, combining immunomodulatory and anti-inflammatory advantages. Regulatory review focuses on the scientific rationale for multi-oil ratios.
Rich in ω-3 fatty acids (EPA/DHA) with anti-inflammatory and immunomodulatory effects. ω-3 source identification and content determination methods present unique analytical challenges.
Olive oil as the primary oil phase, rich in monounsaturated fatty acids with superior oxidative stability over soybean oil-based products. Registration strategy emphasizes "differentiated clinical advantage" substantiation.
Third-generation lipid emulsion — structured triglycerides produced by chemical interesterification of LCT and MCT, offering superior metabolic behavior. This product presents extremely high technical barriers.
Using lipid emulsion as a carrier to deliver poorly water-soluble drugs is one of the most commercially valuable directions in complex injectables. Global annual sales of propofol emulsion injection exceed USD 3 billion, and competition in the domestic generic market is shifting from "can you make it" to "can you produce it consistently at scale" — which is precisely Taikomed's core advantage.
Post-drug-loading emulsion physical stability drops significantly: free fatty acid elevation accelerates, particle size distribution trends toward bimodal patterns, and Zeta potential absolute values decrease. The true barriers lie in: ① DoE design space definition for high-pressure homogenization parameters; ② Balancing optimization between drug loading and physical stability; ③ Controllable impact of sterilization process on particle size/PDI; ④ Method validation for free drug content detection.
| Product | Indication | Registration Category | Core R&D Challenges | Taikomed Technical Strategy |
|---|---|---|---|---|
| Propofol Emulsion Injection | Intravenous general anesthesia | Category 4 Generic | Post-drug-loading PFAT5 easily exceeds limits; particle size change before/after sterilization; viscosity issues with 10% formulations | Staged homogenization + phospholipid/oleic acid synergistic stabilization + rotary autoclave parameter optimization |
| Etomidate Lipid Emulsion Injection | General anesthesia induction | Category 4 Generic | Etomidate oil-phase solubility; emulsifier ratio screening; pH impact on drug stability | Oil-phase solubility pre-screening + DoE emulsifier formulation optimization + pH buffer system design |
| Flurbiprofen Axetil Injection | Postoperative analgesia | Category 4 Generic | Synthesis quality of flurbiprofen axetil prodrug; esterase hydrolysis stability; encapsulation efficiency | Prodrug quality studies + encapsulation efficiency maximization via formulation optimization + free drug UPLC-MS detection |
| Clevidipine Emulsion Injection | Hypertensive emergency | Category 3 Generic | Chemical stability of clevidipine in lipid emulsion; pH and temperature sensitivity | pH buffer + antioxidant combination strategy + accelerated/long-term stability validation protocol |
| Alprostadil Lipid Emulsion Injection | Microcirculation improvement | Category 4 Generic | Alprostadil instability (photodegradation/thermal/oxidative); ultra-low concentration content uniformity | Light-protected processing + nitrogen-blanketed filling + trace API content uniformity control |
Multi-chamber bags (multi-compartment infusion bags) represent the highest packaging-technology barrier in parenteral nutrition products — lipid emulsion, amino acid, and glucose solutions are independently sealed in three separate chambers and mixed by squeezing prior to administration. R&D involves not only the formulation itself but also multi-chamber container material screening, inter-chamber substance migration studies, and in-use stability — spanning multiple cross-disciplinary domains. Currently, the keyword "multi-chamber bag injection CRO" has virtually zero competitor coverage in domestic search engines.
The classic parenteral nutrition 3-chamber bag product — lipid emulsion (soybean oil/MCT), amino acid solution, and glucose solution independently packaged in three chambers. Tear the seal strip, mix, and infuse intravenously.
A 3-chamber bag product with olive oil as the primary oil phase. Olive oil is rich in monounsaturated fatty acids, offering superior oxidative stability and lower lipid peroxidation risk compared to soybean oil-based products.
The core of 3-chamber bags lies not only in the formulation but also in the study and validation of the multi-chamber packaging material system — one of the most highly scrutinized areas during regulatory review.
3-chamber bags are classified as drug-device combination products, with registration submissions involving both drug review (CDE) and packaging system evaluation — significantly more complex than standard injections. Taikomed has complete experience in completing 3-chamber bag product registration submissions.
Category 2.2 modified new drugs (dosage form modification) represent a policy-encouraged direction — offering a 3-5 year market exclusivity monitoring period. Taikomed has deep project accumulation in lipid emulsion dosage form modification, covering TCM monomers, natural drugs, and chemical drug lipid emulsion formulation development.
Curcuma oil exhibits anti-tumor and anti-viral activities. Using lipid emulsion as a carrier to develop an intravenous injection, improving curcuma oil's water insolubility and bioavailability.
Silymarin has extremely low oral bioavailability (<5%). Developing an oral emulsion with lipid emulsion as a carrier significantly enhances liver targeting and absorption efficiency.
The antimalarial drug artesunate has poor water solubility and a short half-life. Lipid emulsion carrier enables sustained release and liver-targeted delivery, extending the duration of effective plasma concentration.
Calcitriol is active vitamin D₃, used for renal osteodystrophy and hypoparathyroidism. Lipid emulsion carrier significantly boosts the bioavailability of this water-insoluble drug.
Active constituents of Ginkgo biloba extract (ginkgolides, flavonoid glycosides) have poor water solubility. Lipid emulsion/liposome carriers significantly improve brain-targeted delivery efficiency.
The registration strategy for modified new drugs directly determines market competitiveness and product lifecycle. Taikomed provides complete consulting from project feasibility assessment and clinical advantage substantiation to regulatory pathway selection.
From reference listed drug characterization to regulatory approval, every R&D stage for lipid emulsion products has its unique process challenges and quality control requirements.
API physicochemical property characterization, oil-phase/emulsifier solubility screening, API saturation solubility in oil phase
Oil/water phase ratio optimization, phospholipid/surfactant DoE screening, coarse emulsion preparation methods (high-shear/ultrasonication)
Homogenization pressure/cycles/temperature DoE optimization, lab→pilot→production scale-up, particle size PDI control
Rotary autoclave sterilization validation, pre-/post-sterilization CQA comparison, related substances/free fatty acids/lyso-phospholipids
Container compatibility (extractables/leachables), 3-chamber bag inter-chamber migration, stress+accelerated+long-term stability
CTD dossier writing (M2-M3 focus), registration strategy development, deficiency response studies, on-site inspection preparation
Lipid emulsion formulation R&D is critically dependent on equipment capability and process know-how. Taikomed has established systematic capabilities in the following key technical domains.
Proficiency in both high-pressure homogenization (Niro Soavi/GEA type) and microfluidization (Microfluidizer) technology routes. Mature design space established for homogenization pressure (500-1500 bar), cycle count (3-15 cycles), and temperature control (40-75°C), supporting linear scale-up from lab 50 mL to pilot 50 L scale.
A multi-method characterization system using dynamic light scattering (DLS/Malvern Zetasizer for mean particle size and PDI), laser diffraction (LD/Mastersizer for large particle tail distribution), NTA (nanoparticle tracking analysis), and PFAT5 (large globule tail method, pharmacopoeia key indicator LM-SP method).
Systematic screening platform for phospholipids (egg yolk lecithin E80/S100, soybean lecithin), non-ionic surfactants (poloxamer 188/F68, polysorbate 80), and auxiliary stabilizers (sodium oleate, sodium cholate). Deep quality control experience with phospholipid source, oxidation status, and lyso-phospholipid content.
Systematic validation of rotary autoclave sterilization for lipid/drug-loaded emulsions (121°C/15 min and 115°C/30 min routes). Key focus on pre-/post-sterilization CQA changes: mean particle size Δ<5%, PDI Δ<0.05, PFAT5 Δ<0.01%, Zeta potential Δ<5 mV, pH Δ<0.3.
Established multiple methods — ultrafiltration centrifugation (Amicon Ultra/MWCO 30 kDa), solid-phase extraction (SPE), and size-exclusion chromatography (SEC) — to separate free drug from encapsulated drug, coupled with HPLC/UPLC/MS analysis for precise free drug quantification. Completed method validation (specificity, LOQ<0.1 µg/mL, recovery 95-105%).
Established 3-chamber bag container material screening and compatibility study system: extractables profiling (GC-MS/LC-MS), specific migration limit (SML) method development and validation, seal strip peelability studies, long-term inter-chamber substance migration kinetics, and 24-h post-mixing in-use stability verification.
Different registration categories for lipid emulsion products correspond to markedly different R&D strategies, review focus areas, and market returns. Taikomed provides complete strategy consulting from project feasibility assessment to regulatory pathway selection.
Lipid emulsion formulation R&D is an entire chain, and every decision point requires professional technical support. The following are the service areas closely related to lipid emulsion / DLE / MCB development:
API physicochemical property characterization, oil-phase solubility screening, logP determination, API-excipient compatibility pre-screening. Provides scientific basis for lipid emulsion carrier selection.
Learn More →DoE optimization of lipid emulsion formulations, HPH/microfluidizer process parameter screening, process design space establishment and control strategy formulation.
Learn More →Particle size/PDI/PFAT5 method validation, free drug detection methods, related substances HPLC methods, sterility/endotoxin testing.
Learn More →Rotary autoclave sterilization process development and validation, pre-/post-sterilization CQA comparison, filter compatibility and sterilizing filtration validation.
Learn More →CTD dossier writing (M2-M3), registration strategy development (Category 4/3/2.2), deficiency response studies and query reply.
Learn More →BE protocol design (reference product selection, subject enrollment, sampling time points), endogenous substance correction, statistical analysis plan.
Learn More →Beyond lipid emulsion / DLE / MCB, Taikomed has also established complete technology platforms in sustained/controlled release formulations and nano drug delivery systems.
Matrix, membrane-controlled, osmotic pump, and pulsatile release — covering all four SR/CR technology routes. Six-step end-to-end R&D services from RLD characterization to regulatory submission.
Explore SR/CR Platform →Liposomes, nanoparticles, lipid emulsions/DLE, microemulsions — covering all four mainstream nano drug delivery systems. Supporting generic development, Category 2.2 modified new drugs, and complex injectables.
Explore Nano Delivery Platform →The BE challenges for lipid emulsion injections lie in: ① Intravenous administration bypasses the absorption phase — BE evaluation relies on plasma drug concentration-time curves, demanding extremely high analytical method sensitivity (LOQ at ng/mL level); ② Interference from endogenous substances (e.g., triglycerides, phospholipids) requires systematic method validation and baseline correction; ③ Lipid emulsions are complex heterogeneous systems, and their in vivo drug release behavior is influenced by multiple factors including droplet size, surface charge, and phospholipid composition — BE non-equivalence may stem from formulation process differences rather than the API itself. Taikomed integrates BE requirements into process development considerations starting from the preformulation stage to reduce late-stage BE failure risk.
3-chamber bags are considered drug-device combination products, and review difficulty is significantly higher than for standard injections or single lipid emulsion injections. Three additional focus areas: ① Multi-chamber container material safety (extractables/leachables studies must follow CDE's Technical Guideline for Compatibility Study of Chemical Injectable Drug Products with Pharmaceutical Glass and Plastic Packaging Materials); ② Inter-chamber seal integrity (dye penetration test, microbial challenge test, long-term storage seal strip peelability); ③ Post-mixing in-use physical stability (particle size trend over 24 h after mixing lipid emulsion and amino acids, PFAT5, Zeta potential). Taikomed has complete experience in completing 3-chamber bag product registration submissions.
Post-sterilization particle size increase and PDI broadening in drug-loaded emulsions are universal industry pain points. Taikomed's solution strategy operates on three levels: ① Formulation — DoE optimization of phospholipid and auxiliary stabilizer (oleic acid, cholic acid) ratios to maximize droplet interfacial film stability at high temperatures; ② Process — Staged homogenization strategy (coarse homogenization → intermediate testing → fine homogenization) with appropriately reduced homogenization pressure during the fine stage to leave a particle size growth margin for sterilization; ③ Sterilization — Rotary autoclave parameter optimization (temperature-time curve, rotation speed, loading configuration) to minimize sterilization-induced perturbation of emulsion microstructure. Target: mean particle size change <5%, PDI change <0.05, PFAT5 change <0.01% pre- vs. post-sterilization.
CDE's clinical advantage substantiation requirements for Category 2.2 modified new drugs are becoming increasingly stringent. Clinical advantage pathways for lipid emulsion formulation modification include: ① Pharmacokinetic advantage — PK studies demonstrating improvements in AUC, Cmax, Tmax, and half-life (e.g., extended half-life enabling reduced dosing frequency); ② Safety advantage — Clinical safety data demonstrating lower injection site irritation, hemolysis, and allergic reaction rates vs. the original dosage form; ③ Efficacy advantage — Clinical efficacy studies (Phase II/III) demonstrating non-inferiority or superiority of the modified formulation; ④ Compliance advantage — e.g., converting a multi-daily-dose conventional injection to a once-daily lipid emulsion long-acting injection. Taikomed can assist in designing complete clinical development programs from PK to confirmatory clinical trials.
Taikomed offers flexible R&D collaboration models: ① Full-process contract R&D (CRO) — Complete commissioned R&D from preformulation to CTD dossier writing; ② Staged contracting — Commissioning only specific phases (e.g., formulation/process development only, quality research only, BE protocol design only); ③ Technology transfer — Transfer of mature, developed formulations/processes to partners for subsequent industrialization; ④ Joint development — Shared R&D investment and commercialization returns with partners. Specific collaboration models can be flexibly customized based on product characteristics and commercialization needs.
Whether it's a parenteral nutrition lipid emulsion generic, drug-loaded emulsion injection development, or 3-chamber bag product portfolio planning, Taikomed provides end-to-end services from DoE formulation optimization to CTD dossier writing.
Inquire Now View Full-Process Services